Avantex Biotechnologies Inc.
A synergistic nanotechnology dual-drug delivery platform for eye care medical treatments, anti-cancer medical therapies, cannabinoid bioavailability, and MRI diagnostics.
Avantex Biotechnologies has developed Acufilic™ – a groundbreaking nanotechnology-based, dual-drug delivery platformthat improves medical therapeutic and treatment outcomes.
Developed by a team of scientific researchers, this new platformenables the co-delivery of drugs to fuse into nanoparticles with targeting and imaging functions– all produced in a streamlined, self-assembly manufacturing process. The particles are small enough to enter tissue and bind to specific targets, resulting in more efficient therapeutic outcomes.
Avantex’s Acufilic™technology allows for lower dosages and lower toxicity with limited side effects. The Acufilic™ nanotechnology provides affordable and efficacious treatments for patients, resulting in better patient compliance and improved outcomes.
In addition, Acufilic™enables cannabinoids to be infused into beverages without impacting the flavour and aroma of the final products. Acufilic™ can enhance the taste and provide long-term release, enabling other ground-breaking cannabis based advanced dosage forms to come to market.
The Avantex Acufilic™ Advantage and Core Nanotechnology
Our core nanotechnology platform features considerable product advantages including:
- Amphiphilicity
- Water soluble
- High drug encapsulation efficiency
- Excellent biocompatibility and bioavailability
- Multi-functionalization
- Controlled release
- Streamlined manufacturing process
A synergistic nanotechnology dual-drug delivery platform for eye care medical treatments, anti-cancer medical therapies, cannabinoid bioavailability, and MRI diagnostics.
Avantex Biotechnologies has developed Acufilic™ – a groundbreaking nanotechnology-based, dual-drug delivery platformthat improves medical therapeutic and treatment outcomes.
Developed by a team of scientific researchers, this new platformenables the co-delivery of drugs to fuse into nanoparticles with targeting and imaging functions– all produced in a streamlined, self-assembly manufacturing process. The particles are small enough to enter tissue and bind to specific targets, resulting in more efficient therapeutic outcomes.
Avantex’s Acufilic™technology allows for lower dosages and lower toxicity with limited side effects. The Acufilic™ nanotechnology provides affordable and efficacious treatments for patients, resulting in better patient compliance and improved outcomes.
In addition, Acufilic™enables cannabinoids to be infused into beverages without impacting the flavour and aroma of the final products. Acufilic™ can enhance the taste and provide long-term release, enabling other ground-breaking cannabis based advanced dosage forms to come to market.
The Avantex Acufilic™ Advantage and Core Nanotechnology
Our core nanotechnology platform features considerable product advantages including:
- Amphiphilicity
- Water soluble
- High drug encapsulation efficiency
- Excellent biocompatibility and bioavailability
- Multi-functionalization
- Controlled release
- Streamlined manufacturing process
Experienced Management Team
Avantex Biotechnologies Inc. is managed by a knowledgeable and motivated team of professionals with extensive international experience and a broad range of biotechnology industry skills.
• Nikita Chou, MBA – President and Director
• John Gan – Chief Financial Officer and Director
• Andrew Csinger, B.Eng, PhD – Chief Strategy Officer
• Ullrich Schade – Vice President, Marketing
• Vlad Budzynski, M.D, PhD. – Biotechnology Advisor
• Deanmo Liu, Ph.D – Scientific Advisor
• Dr. Louis Liu, MD, Ph.D – Medical Advisor
• Dan Cohen – Vice President, Corporate Strategy